Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 8, 2015, Pages 701-706

  Talib, L L ^a   Hototian, S R ^a   Joaquim, H P G ^a   Forlenza, O V ^a   Gattaz, W F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer disease; Donepezil; Glycogen synthase kinase 3; Phospholipase A2; Platelets

Indexed keywords

CALCIUM INDEPENDENT PHOSPHOLIPASE A2; DONEPEZIL; GLYCOGEN SYNTHASE KINASE 3BETA; CHOLINESTERASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; INDAN DERIVATIVE; PHOSPHOLIPASE A2 GROUP VI; PIPERIDINE DERIVATIVE; PLA2G6 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITION ASSESSMENT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MALE; NEUROPHARMACOLOGY; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY; THROMBOCYTE; ANALYSIS OF VARIANCE; BLOOD; ENZYMOLOGY; MENTAL HEALTH; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BLOOD PLATELETS; CHOLINESTERASE INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GROUP VI PHOSPHOLIPASES A2; HUMANS; INDANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PHOSPHORYLATION; PIPERIDINES; TIME FACTORS;

EID: 84944352898     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-015-0600-6     Document Type: Article

References (45)

1. Leyhe T, Hoffmann N, Stransky E, Laske C (2009) Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer’s disease. Int J Neuropsychopharmacol 12(10):1319–1326
2. Shen H, Kihara T, Hongo H, Wu X, Kem WR, Shimohama S, Akaike A, Niidome T, Sugimoto H (2010) Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol 161(1):127–139
3. Noh MY, Koh SH, Kim SM, Maurice T, Ku SK, Kim SH (2013) Neuroprotective effects of donepezil against Aβ42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3β and nAChRs activity. J Neurochem 127(4):562–574
4. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am J Psychiatry 162(4):676–682
5. Talib LL, Diniz BS, Zainaghi IA, Forlenza OV, Gattaz WF (2012) A radioenzymatic assay to identify three groups of phospholipase A(2) in platelets. Prostaglandins Leukot Essent Fatty Acids 86(4–5):149–153
6. Schaloske RH, Dennis EA (2006) The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761(11):1246–1259 (Review)
7. Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50(Suppl):S237–S242 (Review)
8. Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269(18):13057–13060
9. Lambeau G, Gelb MH (2008) Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77:495–520
10. Schaeffer EL, Skaf HD, Novaes Bde A, da Silva ER, Martins BA, Joaquim HD, Gattaz WF (2011) Inhibition of phospholipase A2 in rat brain modifies different membrane fluidity parameters in opposite ways. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1612–1617
11. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45(2):205–213
12. Schaeffer EL, Forlenza OV, Gattaz WF (2009) Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology 202(1–3):37–51
13. Schaeffer EL, da Silva ER, Novaes Bde A, Skaf HD, Gattaz WF (2010) Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 34(8):1381–1389
14. Forlenza OV, Mendes CT, Marie SK, Gattaz WF (2007) Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukot Essent Fatty Acids 76:47–55
15. De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV (2010) Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids 82:57–60
16. Schaeffer EL, Gattaz WF (2005) Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology 181:392–400
17. Schaeffer EL, Gattaz WF (2007) Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats. J Neural Transm 114:379–385
18. Schaeffer EL, Zorron PuL, Gagliotti DA, Gattaz WF (2009) Conditioning training and retrieval increase phospholipase A(2) activity in the cerebral cortex of rats. J Neural Transm 116:41–50
19. Gattaz WF, Maras A, Cairns NJ, Levy R, Förstl H (1995) Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry 37:13–17
20. Gattaz WF, Cairns NJ, Levy R, Förstl H, Braus DF, Maras A (1996) Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 246(3):129–131
21. Talbot K, Young RA, Jolly-Tornetta C, Lee VM, Trojanowski JQ, Wolf BA (2000) A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem Int 37(1):17–31
22. Forlenza OV, Wacker P, Nunes PV, Yacubian J, Castro CC, Otaduy MC, Gattaz WF (2005) Reduced phospholipid breakdown in Alzheimer’s brains: a 31P spectroscopy study. Psychopharmacology 180(2):359–365
23. Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519–527
24. Chin PC, Majdzadeh N, D’Mello SR (2005) Inhibition of GSK3b is a common event in neuroprotection by different survival factors. Mol Brain Res 137:193–201
25. Balaraman Y, Limaye ER, Levey AI, Srinivasan S (2006) Glycogen synthase kinase 3B and Alzheimer’s disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 63:1226–1235
26. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577–595
27. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT et al (2008) The role of gsk-3 in synaptic plasticity. Br J Pharmacol 153(Suppl. 1):S428–S437
28. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S et al (2008) Glycogen synthase kinase-3b, or a link between amyloid and tau pathology? Genes. Brain Behav 7:57–66
29. Grimes CA, Jope RS (2001) The multifaceted roles of GSK3b in cellular signaling. Prog Neurobiol 65:391–426
30. Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30:1223–1237
31. Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269:14566–14574
32. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123(1):224–235
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944
34. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX: a standardized Instrument for the diagnosis of mental disorders in the elderly with special reference to early detection of dementia. Br J Psychiatry 149:698–709
35. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
36. Talib LL, Yassuda MS, Diniz BS, Forlenza OV, Gattaz WF (2008) Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukot Essent Fatty Acids 78:265–269
37. Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HP, Diniz BS (2011) Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res 45(2):220–224
38. Diniz BS, Talib LL, Joaquim HPG, De-Paula VRJ, Gattaz WF, Forlenza OV (2011) Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry 12(3):216–222
39. Joaquim HP, Talib LL, Forlenza OV, Diniz BS, Gattaz WF (2012) Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. J Psychiatr Res 46(8):1053–1058
40. Selkoe DJ (2004) American College of Physicians; American Physiological Society. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 140(8):627–638 (Review)
41. Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH (2009) Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem 108(5):1116–1125
42. 2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study. J Neural Transm 121(2):193–200
43. Smesny S, Stein S, Willhardt I, Lasch J, Sauer H (2008) Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia. J Neural Transm 115(8):1173–1179
44. Akasofu S, Kimura M, Kosasa T, Ogura H, Sawada K (2006) Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicity. Eur J Pharmacol 530(3):215–222
45. Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF, Vidic J, de BarryJ Chasserot-Golaz S, Delalande F, Van Dorsselaer A, Schneider F, Helle K, Aunis D, Prévost G, Metz-Boutigue MH (2009) Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE 4(2):e4501